SAGE-718
718-CLP-102 B
Phase 2 small_molecule completed
Quick answer
SAGE-718 for Huntington Disease is a Phase 2 program (small_molecule) at SUPERNUS PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- SUPERNUS PHARMACEUTICALS, INC.
- Indication
- Huntington Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed